These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
227 related articles for article (PubMed ID: 8549361)
1. Epidemiology of quinolone resistance: Europe and North and South America. Goldstein FW; Acar JF Drugs; 1995; 49 Suppl 2():36-42. PubMed ID: 8549361 [TBL] [Abstract][Full Text] [Related]
2. The epidemiology of bacterial resistance to quinolones. Acar JF; O'Brien TF; Goldstein FW; Jones RN Drugs; 1993; 45 Suppl 3():24-8. PubMed ID: 7689447 [TBL] [Abstract][Full Text] [Related]
5. In vitro antimicrobial activity of fluoroquinolones against clinical isolates obtained in 1989 and 1990. Chen YC; Chang SC; Hsu LY; Hsieh WC; Luh KT J Formos Med Assoc; 1993 Dec; 92(12):1040-8. PubMed ID: 7911351 [TBL] [Abstract][Full Text] [Related]
6. Assessment of pathogen frequency and resistance patterns among pediatric patient isolates: report from the 2004 SENTRY Antimicrobial Surveillance Program on 3 continents. Fedler KA; Biedenbach DJ; Jones RN Diagn Microbiol Infect Dis; 2006 Dec; 56(4):427-36. PubMed ID: 16938419 [TBL] [Abstract][Full Text] [Related]
7. Prevalence of fluoroquinolone resistance in Europe. Study Group 'Bacterial Resistance' of the Paul-Ehrlich-Society for Chemotherapy e. V. Kresken M; Hafner D; Mittermayer H; Verbist L; Bergogne-Bérézin E; Giamarellou H; Esposito S; van Klingeren B; Kayser FH; Reeves DS Infection; 1994; 22 Suppl 2():S90-8. PubMed ID: 7927836 [TBL] [Abstract][Full Text] [Related]
15. Activity of gatifloxacin tested against isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (North America, 1998-2003). Fedler KA; Jones RN; Sader HS; Fritsche TR Diagn Microbiol Infect Dis; 2006 Jun; 55(2):157-64. PubMed ID: 16529904 [TBL] [Abstract][Full Text] [Related]
16. [Impact of fluoroquinolone use on multidrug-resistant bacteria emergence]. Nseir S; Ader F; Marquette CH; Durocher A Pathol Biol (Paris); 2005; 53(8-9):470-5. PubMed ID: 16176863 [TBL] [Abstract][Full Text] [Related]
17. Lomefloxacin (SC-47111 or NY-198). Comparative antimicrobial activity against 2002 clinical isolates from hospitals in Mexico City. Durazo F; Resano F; Gonzalez MA Diagn Microbiol Infect Dis; 1990; 13(1):71-5. PubMed ID: 2331854 [TBL] [Abstract][Full Text] [Related]
18. Rufloxacin (MF-934): in vitro and in vivo antibacterial activity. Ravizzola G; Pinsi G; Pirali F; Colombrita D; Foresti I; Peroni L; Turano A Drugs Exp Clin Res; 1989; 15(1):11-5. PubMed ID: 2743869 [TBL] [Abstract][Full Text] [Related]
19. Potency and spectrum of garenoxacin tested against an international collection of skin and soft tissue infection pathogens: report from the SENTRY antimicrobial surveillance program (1999-2004). Fritsche TR; Sader HS; Jones RN Diagn Microbiol Infect Dis; 2007 May; 58(1):19-26. PubMed ID: 17383139 [TBL] [Abstract][Full Text] [Related]
20. Emergence of multidrug-resistant Streptococcus pneumoniae: report from the SENTRY Antimicrobial Surveillance Program (1999-2003). Johnson DM; Stilwell MG; Fritsche TR; Jones RN Diagn Microbiol Infect Dis; 2006 Sep; 56(1):69-74. PubMed ID: 16546341 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]